Introduction {#Sec1}
============

Each year, approximately 4000 lung transplantations are performed worldwide ([ISHLT.org](http://ishlt.org)). Many of these lung transplantation patients develop acute kidney injury (AKI) \[[@CR1]--[@CR3]\]. Prevention of AKI in lung transplant recipients is vital because it is associated with the development of chronic kidney disease (CKD) increasing morbidity and mortality \[[@CR2]\]. AKI in the first days after transplantation may be due to shock, systemic inflammation, and/or nephrotoxic drugs \[[@CR4]--[@CR6]\]. One such nephrotoxic drug is tacrolimus, a very effective immunosuppressant belonging to the calcineurin inhibitor class and ubiquitously used in lung transplant patients \[[@CR7]--[@CR11]\].

Tacrolimus nephrotoxicity in the early phase after transplantation is associated with several pharmacokinetic factors, which influence tacrolimus blood concentrations profoundly. For instance, the bioavailability of tacrolimus is highly variable due to gut dysmotility, changes in metabolism, and altered clearance due to liver injury \[[@CR12]\]. Furthermore, tacrolimus metabolism may change with drug-drug interactions by inhibiting or competing with the transporter P-glycoprotein (Pgp) and the enzymes cytochrome P450 (CYP) 3A4/5 \[[@CR13], [@CR14]\]. These variations in pharmacokinetics in the early phase may result in high fluctuations in the whole-blood tacrolimus concentrations, increasing tacrolimus toxicity and decreasing tacrolimus efficacy \[[@CR15], [@CR16]\].

We hypothesized that tacrolimus nephrotoxicity might have a crucial role in the development of AKI after lung transplantation. Therefore, the purpose of this retrospective study was to investigate the development and recovery of kidney injury after lung transplantation and relate AKI to whole-blood tacrolimus trough concentrations.

Patients and methods {#Sec2}
====================

All lung transplantation patients hospitalized at the University Medical Center Utrecht (UMCU) from July 2001 to February 2011 were retrospectively studied. Tacrolimus whole-blood trough concentrations were analyzed during the first year post transplantation. The immunosuppressive regimen consisted further of basiliximab, corticosteroids, and mycophenolate mofetil. Cofactors influencing tacrolimus blood concentrations and renal function were recorded as well. AKI was defined by the "Kidney Disease: Improving Global Outcomes" (KDIGO) Clinical Practice Guideline criteria and CKD by the "CKD Epidemiology Collaboration equation" (CKD-EPI). Both were solely based on measurement of creatinine. For more detailed information on the variables, covariates, and the used statistical analyses, see the supplemental text "[Patients and Methods](#Sec2){ref-type="sec"}."

Results {#Sec3}
=======

Patients' characteristics {#Sec4}
-------------------------

A total of 186 patients were included. Twenty-nine patients died in the first year, 11 of whom within 14 days. Patients died of bleeding (9), heart failure (1), primary graft failure (1), acute rejection (1), infection (5), hemorrhagic cerebrovascular accident (3), chronic respiratory failure (4), carcinoma (1), or an unknown cause (4). Two peaks in the age distribution were observed (Fig. [1](#Fig1){ref-type="fig"}a). The category 18--40 years contained significantly more cystic fibrosis (CF) patients than the category \>40 years (*χ* ^2^ 88.09, 2 df, *p* \< 0.001). Table [1](#Tab1){ref-type="table"} shows the patients' characteristics. The main differences between the two groups, "AKI" or "no AKI," involved the frequency of CF patients, the frequency of perioperative extracorporeal membrane oxygenation (ECMO), and the frequency of occurrence of infection. Further, systemic inflammatory response syndrome (SIRS) was most frequently observed on day 2 (89%, 159 out of 186) and shock on day 1 (48%, 88 out of 186). On day 6, these percentages were decreased to 34% (61 out of 186) and 5% (8 out of 186), respectively.Fig. 1**a** Histogram of age in years. **b** Prevalence of AKI per day between day 1 and month 1 by stage in 3 stages. **c** Serum creatinine over time as mean and SD. **d** Whole-blood tacrolimus trough concentrations over time (*box*: 25th, median, and 75th percentiles); the *asterisks* in the *boxplots* show that the medians on day 4 and 5 were significantly different from 15 ng/mL on day 4 and 5 Table 1Patients' characteristicsVariablesAll patients\
*N* = 186 (100%)Follow up ≥ day 14 and no AKI day 2--14\
*N* = 87 (47%)Follow up ≥ day 14 and AKI day 2--14\
*N* = 85 (46%)*P* value^a^*N* (%)Male91 (49%)36 (41%)47 (55%)0.07Death day 1--1411 (6%)0 (0%)0 (0%)--^b^Death day 1--1 year29 (16%)1 (1%)17 (20%)\< 0.001Reason transplantation*------*0.03CF57 (31%)17 (20%)33 (39%)0.005COPD, emphysema, alpha-1-antitrypsin deficiency80 (43%)48 (55%)28 (33%)0.003Sarcoidosis/ILD/UIP14 (8%)7 (8%)6 (7%)0.81Others: PAH, IPF, bronchiectasis, allergic alveolitis, LCH, LAM35 (19%)15 (17%)18 (21%)0.51Double transplantation148 (80%)64 (74%)73 (86%)0.045Diabetes mellitus40 (22%)13 (15%)21 (25%)0.11Preoperative ECMO1 (0.5%)1 (1%)0 (0%)1.00Perioperative ECMO118 (63%)45 (52%)62 (73%)0.004ICU admission before19 (10%)7 (8%)11 (13%)0.29Complications91 (49%)35 (40%)45 (53%)0.10Reoperation due to bleeding43 (23%)13 (15%)20 (24%)0.15Infection48 (26%)15 (17%)33 (39%)0.002Rejection22 (12%)7 (8%)14 (17%)0.09Other27 (15%)9 (10%)17 (20%)0.08At least once during day 1--6Liver injury53 (29%)17 (20%)31 (37%)0.013Anemia182 (98%)85 (98%)85 (100%)0.50Low protein concentration129 (69%)58 (67%)65 (77%)0.15Supra-therapeutic whole-blood tacrolimus trough concentration135 (73%)61 (70%)71 (84%)0.04SIRS172 (93%)81 (93%)81 (95%)0.7Shock115 (62%)47 (54%)61 (72%)0.016At least one drug increasing tacrolimus concentration181 (97%)85 (98%)85 (100%)0.50At least one drug decreasing tacrolimus concentration157 (84%)71 (82%)78 (92%)0.05Nephrotoxic drugs other than tacrolimus178 (96%)85 (98%)83 (98%)1.0Mean (SD)*P* value ^a^Age (year)46 (13.3)47 (12.8)45 (13.9)0.2BMI22 (3.7)23 (3.6)22 (3.8)0.8^a^Chi-square test, Fisher's exact test, or *t* test where appropriate^b^No statistics are computed because no death occurred

Mean baseline creatinine was 71 μmol/L (SD 35 μmol/L). Within the first 14 days after transplantation, 85 patients (46%) developed AKI (all three AKI stages pooled together) (Fig. S[2](#MOESM1){ref-type="media"}). Forty-two percent of the patients (78 out of 186) presented at least one episode of AKI between day 1 and day 6. The frequency of AKI was highest on day 3 (24%, *N* = 43 out of 175). The most serious AKI ("AKI stage 3") was especially frequent within the first 2 weeks after transplantation and occurred most often on days 6 and 7 (3.5%; 6 out of 173) (Fig. [1](#Fig1){ref-type="fig"}b). Figure [1](#Fig1){ref-type="fig"}c shows the early peak in serum creatinine with a partial decrease up to 1 month and hereafter a slow increase in serum creatinine over time. Renal replacement therapy was needed in 9% of patients on the intensive care (17 out of 186). Almost all patients received nephrotoxic drugs other than tacrolimus within the first week after transplantation (96% of patients) (Table [1](#Tab1){ref-type="table"}). On day 2, most patients received nephrotoxic drugs other than tacrolimus (73%; 130 out of 179). The differences in patient numbers arise from transfer to another hospital, death, and the discontinuation of tacrolimus (Fig. S[2](#MOESM1){ref-type="media"}).

Variables influencing whole-blood tacrolimus concentrations {#Sec5}
-----------------------------------------------------------

As can be seen in Fig. [1](#Fig1){ref-type="fig"}, the median whole-blood tacrolimus trough concentration first increases and then levels off. Between day 1 and day 6, 73% of patients showed supra-therapeutic concentrations (135 out of 186). Supra-therapeutic concentrations were observed most often on days 4 and 5 (50%; 87 out of 174, and 54%; 93 out of 174 of patients). At 6 months, 10% of patients (16 out of 107) showed elevated tacrolimus concentrations. Whole-blood tacrolimus trough concentrations differed significantly over time (day (estimate 1.24, 95% CI 1.02 to 1.46) and day squared (estimate −0.13, 95% CI −0.15 to −0.10)) (Table [2](#Tab2){ref-type="table"}). Cystic fibrosis was significantly related to supra-therapeutic concentrations (estimate −0.16, 95% CI −0.28 to −0.03).Table 2Linear mixed model to test the variables influencing whole-blood tacrolimus trough concentrationsFixed effectEstimate^ab^95% CI• CF−0.16−0.28−0.03• Liver injury0.04−0.080.16• Drugs increasing tacrolimus−0.02−0.090.05• ≥2 drugs increasing tacrolimus−0.13−0.250.00• 1 or 2 drugs decreasing tacrolimus−0.06−0.130.01• Day1.241.021.46• Day squared^c^−0.13−0.15−0.10^a^Estimate = regression coefficient in a linear mixed model, with log (tacrolimus concentration) as outcome variable^b^Estimate of intercept = −0.19^c^A quadratic term is included in the model because there was no linear relationship between outcome variable and factors included in the model

Patients often received at least one drug that could increase tacrolimus concentrations (e.g., 81% of patients on day 1 (149 out of 184) and 36% on day 5 (63 out of 173) and within 2 weeks 97%) (Table [1](#Tab1){ref-type="table"}). At the same time, they also frequently received drugs that could decrease whole-blood tacrolimus concentrations (e.g., 63% on day 2 (112 out of 179) and 37% on day 5 (64 out of 173) and within 2 weeks 84%) (Table [1](#Tab1){ref-type="table"}). Receiving two or more drugs, which potentially increase tacrolimus concentrations, was a significant predictor of a change in concentrations (estimate −0.13, 95% CI −0.25 to −0.00) (Table [2](#Tab2){ref-type="table"}). The groups were too small to differentiate the distinctive drugs.

Variables influencing AKI {#Sec6}
-------------------------

The variables "supra-therapeutic whole-blood tacrolimus trough concentration" (OR 1.55, 95% CI 1.06--2.27), "infection" (OR 2.48, 95% CI 1.31--4.70), "CF" (OR 2.17, 95% CI 1.16-4.06) and \" ≥3 nephrotoxic drugs other than tacrolimus\" (OR 1.96, 95% CI 1.02--3.77) were all significantly associated with AKI in GEE analyses when day 2 to day 6 were concerned (Table [3](#Tab3){ref-type="table"}). When day 2 to day 14 were incorporated, \" supra-therapeutic tacrolimus concentration\" (OR 1.52, 95% CI 1.04--2.24), \"CF\" (OR 2.23, 95% CI 1.26--4.33), and \"infection\" (OR 2.31, 95% CI 1.23--4.34) were significantly associated. These analyses were based on the highest level of tacrolimus obtained, regardless of the duration of the supra-therapeutic concentration.Table 3General estimating equations (GEE) analyses to test the variables influencing AKIDay 2--6^ac^Day 2--14^bd^OR95% CIOR95% CISupra-therapeutic whole-blood tacrolimus trough concentration1.551.062.271.521.042.24SIRS^e^0.920.651.28NAShock^e^1.560.822.95NACF2.171.164.062.331.264.33Nephrotoxic drugs other than tacrolimus^e^NA1 nephrotoxic drug2.040.944.412 nephrotoxic drugs1.400.732.69≥3 nephrotoxic drugs1.961.023.77Double transplantation2.070.775.542.150.815.69Perioperative ECMO1.110.582.101.090.572.06Infection2.481.314.702.311.234.34^a^d2--d6: data concerning day 2 up to day 6^b^d2--d14: data concerning day 2 up to day 14^c^d2--d6: estimate of the intercept −2.96^d^d2--d14: estimate of the intercept −2.82^e^Data not available between day 7 and day 14

Relationship between AKI, recovery, and CKD {#Sec7}
-------------------------------------------

AKI was recovered in 19% of patients (16 out of 85) at 1 month (Fig. S[2](#MOESM1){ref-type="media"}). At 1 year after lung transplantation, the frequency of patients with severe CKD was 15% (23 out of 149 patients still at risk). The frequency of severe CKD for patients with "no-AKI between day 1 and day 14" was 16 out of 84 (19%), for patients with "AKI between day 1 and day 14 with recovery at 1 month" was 2 out of 14 (14%), and for patients with "AKI between day 1 and day 14 without recovery at 1 month" was 5 out of 48 patients (10%). In both groups of patients with AKI, between 14 and 25% of patients were either lost to follow-up, discontinued tacrolimus, and changed to sirolimus or had missing creatinine levels (AKI and recovery 25% (4 out of 16), AKI without recovery 14% (9 out of 64)). The mortality rate in the group of no-AKI was 1% (1 out of 87), in the group of AKI with recovery was 6% (1 out of 16), and in the group of AKI without recovery was 20% (13 out of 64). Significant differences in cumulative incidence of death were observed between the three categories of patients (*p* \< 0.001). Significant differences in cumulative incidence of the combined outcome "death and severe CKD" were also observed between the three categories of patients (*p* = 0.002). The cumulative incidence of death significantly differed between groups 1 and 2 on the one hand and group 3 on the other (*p* \< 0.001). The cumulative incidence of the combined outcome death and severe CKD also differed between groups 1 and 2 on the one hand and group 3 on the other (*p* = 0.001). The mortality rate and severe CKD incidence rate did not differ significantly between CF and non-CF patients (*p* = 0.77 and 0.17, respectively).

Discussion {#Sec8}
==========

We draw three main conclusions from the data with respect to AKI after lung transplantation: (1) it frequently occurs in the first 14 days, (2) it shows low recovery rates and often evolves to severe chronic kidney disease, and (3) it is related to increased whole-blood tacrolimus trough concentrations.

We found high incidence rates of AKI similar to other studies on renal function in lung-transplanted patients treated with tacrolimus \[[@CR2], [@CR17]\]. The high occurrence rate of AKI in lung transplants might be due to a high occurrence rate of clinical instability. We related AKI to the occurrence of infection, and almost all patients exhibited SIRS and shock \[[@CR2]\]. CF patients are especially at risk for AKI, because of a high rate of diabetes and exposure to antimicrobials, and they exhibit a high risk for postoperative complications due to a high rate of infections, hemorrhage, and perioperative ECMO use \[[@CR18], [@CR19]\]. We found that CF was related to supra-therapeutic tacrolimus concentrations as additional risk factor for AKI.

Apart from the high incidence rates of AKI, we observed a low rate of convalescence from AKI. Such low improvement rates of AKI have been reported previously. Wehbe et al. reported that recovery to the pretransplant renal function occurred in 34% of lung transplant patients with AKI \[[@CR2]\]. This is in contrast to patients with septic shock, in which recovery of renal function often occurs (73% of patients) and is, in a large part, complete (60% of patients) \[[@CR20]\]. We further observed that the cumulative incidence of death and severe CKD was significantly higher in the group of patients with AKI that had not recovered at 1 month. This is in accordance with Wehbe et al. \[[@CR2]\]. Additionally, we observed, when no AKI occurred, that almost a fifth of patients developed severe CKD after a year. Moreover, slow deterioration of renal function may very well be related to the continuous administration of tacrolimus because it is one of the main constant nephrotoxic factors in lung transplant patients. This is in accordance with previous findings. A gradual increase of tacrolimus toxicity during the first year after transplantation has been shown in renal biopsies \[[@CR21]\]. Especially, CYP3A5\*3 carriers are associated with increased risk of kidney injury compared to CYP3A5\*1 carriers. It is thought that CYP3A5\*1 carriers are protected from nephrotoxicity due to a decreased exposure to tacrolimus \[[@CR22]--[@CR24]\]. Expression of CYP3A5 presumably has also a role in nephrotoxicity by directly affecting the tubular cells; reduced presence of CYP3A5 within the tubular cells increases nephrotoxicity possibly due to a diminished metabolization of tacrolimus \[[@CR25]\].

A high whole-blood tacrolimus trough level was a risk factor for the development of AKI. Tacrolimus was above the therapeutic range in more than half of the patients in the first 6 days, which emphasizes the challenges of tacrolimus dosing in the early phase after transplantation. In particular, patients with SIRS or septic shock (the majority of patients) may have organ failure, which changes the pharmacokinetics. This, in turn, may lead to these supra-therapeutic whole-blood tacrolimus levels. Also, after recovery from clinical instability, tacrolimus dosage remains challenging. After 6 months, almost one out of ten patients still exhibited supra-therapeutic whole-blood tacrolimus trough levels.

Interestingly, the median whole-blood tacrolimus trough concentrations were not that far above the therapeutic range in the first week after transplantation. This may indicate that the whole-blood tacrolimus trough concentrations were not the only contributing factor to tacrolimus toxicity. We hypothesize that the unbound tacrolimus plasma concentrations are potentially more responsible for the nephrotoxicity than the whole-blood tacrolimus concentrations. Only the unbound plasma concentration of a drug is biologically active and potentially toxic. Tacrolimus is highly bound to erythrocytes, albumin, α1-acid glycoprotein (AGP), and high-density lipoprotein (HDL) in stable clinical conditions, though the capacity of tacrolimus to bind may widely fluctuate in times of systemic inflammation and shock \[[@CR26]\]. Erythrocytes and proteins are known to extensively vary during clinical instability \[[@CR27], [@CR28]\]. Unfortunately, the unbound tacrolimus plasma concentrations cannot be measured by routine analyses. Consequently, knowledge of unbound tacrolimus plasma concentrations is scarce as well as its relation to nephrotoxicity. Our data showed large decreases in the number of erythrocytes and protein levels in the majority of patients in the first week after transplantation (See Table S[3](#MOESM1){ref-type="media"}). These decreases may have influenced unbound plasma concentrations without having an effect on whole-blood concentrations. Therefore, the unbound tacrolimus plasma concentrations may be a more sensitive biomarker of nephrotoxicity.

Remarks regarding this study {#Sec9}
----------------------------

There are some limitations to this study due to the retrospective design. Several explanatory variables influencing the pharmacokinetics of tacrolimus could not be investigated because of the number of missing values. For instance, the effect of variations in variables like acidosis, changes in fluid balance, gut motility, or variations in concentrations and activity of CYP 3A4/5 and P-glycoprotein could not be examined. They all may have an effect on whole-blood tacrolimus concentrations and should be considered as residual confounders.

The whole-blood tacrolimus trough concentrations were measured at approximately 12 h after administration. Tacrolimus elimination half-life time and time to trough level may substantially variate in solid organ recipients \[[@CR29]\]. Therefore, the "apparent" trough levels monitored and used for dose adjustments according to the current practice may not always reflect optimal trough levels \[[@CR30]\].

Cystic fibrosis patients showed unexpectedly higher whole-blood tacrolimus concentrations. Cystic fibrosis patients generally have a decreased bioavailability and higher phase II metabolism resulting in a lower area under the concentration-time curve \[[@CR31], [@CR32]\]. Whether these CF patients received higher doses or had a decreased metabolism due to variations in CYP3A4/5 or P-glycoprotein gene expression and drug-drug interactions could not be determined.

Different definitions of renal function complicate the comparison of the results with other studies \[[@CR1], [@CR17], [@CR33], [@CR34]\]. To allow for a better comparison, we analyzed our data with the criteria used by Wehbe et al., i.e., the KDIGO criteria were used without the urine output \[[@CR2]\]. Plasma creatinine levels in lung transplantation patients after surgery may overestimate renal function due to pronounced muscle loss and depressed production of creatinine, which may result in lower creatinine plasma concentrations and an underestimation of the percentage of kidney injury \[[@CR35], [@CR36]\].

Investigations like ultrasound, biopsy, and urine analyses are not performed at a regular basis in clinically unstable lung transplant patients. Therefore, other causes of kidney injury are not excluded in this cohort and may have had an effect on kidney function. All AKI was attributed to tacrolimus, and this might lead to an overestimation of the nephrotoxicity caused by tacrolimus. Important alternatives are the predisposing factors for AKI, which are shown in Table [1](#Tab1){ref-type="table"}.

Conclusions {#Sec10}
===========

AKI is common after lung transplantation and is associated with both morbidity and mortality. We related supra-therapeutic whole-blood tacrolimus concentrations, next to three or more other nephrotoxic drugs, CF, and infection to AKI in the first week after transplantation. There was a high occurrence of hemodynamic instability perioperatively. Whereas hemodynamic instability is a known cause of AKI, recovery to pretransplant renal function is expected. We observed an ongoing deterioration of renal function even when patients were considered stable. We related supra-therapeutic whole-blood tacrolimus concentrations early after transplantation to the emergence of AKI. This study underlines the significance of unraveling tacrolimus pharmacokinetics early after transplantation in order to decrease AKI in this vulnerable group of patients.
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:   American College of Chest Physicians

AGP
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:   Acute kidney injury
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:   High-density lipoprotein

Ht
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IPF

:   Idiopathic pulmonary fibrosis

LAM

:   Lymphangioleiomyomatosis

LCH

:   Langerhans cell histiocytosis
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:   Odds ratio

PAH

:   Pulmonary arterial hypertension

Pgp

:   P-glycoprotein

SCCM

:   Society of Critical Care Medicine

SD

:   Standard deviation from the mean

SIRS

:   Systemic inflammatory response syndrome

TGF-β1

:   Transforming growth factor β1

Prof. J Meulenbelt, MD, PhD, died in December 2015
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